PDF下载 ( 710 KB)
丙型肝炎病毒感染与器官移植
DOI: 10.12449/JCH240404
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：张莉负责设计论文框架，起草并修改论文；胡鹏负责拟定写作思路，指导撰写文章并最后定稿。
-
摘要: 近年来，在器官移植候选者和受者中预防和治疗HCV的策略发展迅速。尽管HCV感染在肝或非肝实体器官移植中不再威胁移植结果，但它们仍然是研究的焦点。由于丙型肝炎仍然是全球因肝硬化失代偿期、肝衰竭和肝细胞癌而死亡的主要原因，因此需要合适的采取器官移植，以提高生存率和生活质量。而近年来随着HCV阳性实体器官供体的增加，且对器官的需求仍显著超过供应，随着直接抗病毒药物的发展，全球逐渐开展将HCV阳性供体器官移植到HCV阴性受体中，这将可能显著提高移植率并降低等候名单死亡率。目前抗HCV治疗的有效性创造了一个重要的机会，通过增加器官移植的可及性和降低候诊死亡率将显著提高终末器官衰竭患者的生存率。Abstract: In recent years， rapid progress has been made in strategies for the prevention and treatment of hepatitis C virus （HCV） in organ transplant candidates and recipients， and although HCV infections no longer threaten transplantation outcomes in liver or non-hepatic solid organ transplantation， they remain a focus of research. Since hepatitis C is still a leading cause of death worldwide due to decompensated cirrhosis， liver failure， and hepatocellular carcinoma， appropriate organ transplantation is needed to improve survival rate and quality of life. With the increase in HCV-positive solid organ donors in recent years and the fact that the demand for organs still greatly exceeds organ supply， as well as the development of direct-acting antiviral agents， transplantation of HCV-viraemic organs into HCV-naïve recipients will significantly increase transplantation rates and reduce waitlist mortality. The efficacy of current HCV therapies has created an important opportunity to improve the survival rate of patients with end-organ failure by enhancing access to organ transplantation and reducing waitlist mortality.
-
Key words:
- Hepacivirus /
- Antiviral Agents /
- Organ Transplantation
-
[1] WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022— 2030[EB/OL]. World Health Organization, Geneva, 2022. [2] COLLABORATORS POH. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2( 3): 161- 176. DOI: 10.1016/S2468-1253(16)30181-9. [3] COLLABORATORS POH. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6. [4] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Hepatol, 2022, 30( 12): 1332- 1348. DOI: 10.3760/cma.j.cn501113-20221220-00605.中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 12): 1332- 1348. DOI: 10.3760/cma.j.cn501113-20221220-00605. [5] FALADE-NWULIA O, SUAREZ-CUERVO C, NELSON DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review[J]. Ann Intern Med, 2017, 166( 9): 637- 648. DOI: 10.7326/M16-2575. [6] MANSOUR M, HILL L, KERR J. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation[J]. Transpl Infect Dis, 2018, 20( 6): e12972. DOI: 10.1111/tid.12972. [7] GOLDBERG DS, BLUMBERG E, MCCAULEY M, et al. Improving organ utilization to help overcome the tragedies of the opioid epidemic[J]. Am J Transplant, 2016, 16( 10): 2836- 2841. DOI: 10.1111/ajt.13971. [8] YOUNOSSI ZM, WONG G, ANSTEE QM, et al. The global burden of liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 1978- 1991. DOI: 10.1016/j.cgh.2023.04.015. [9] NAKAGAWA M, ASAHINA Y, KAKINUMA S, et al. Impact of eradication of hepatitis C virus on liver-related and-unrelated diseases: Morbidity and mortality of chronic hepatitis C after SVR[J]. J Gastroenterol, 2023, 58( 4): 299- 310. DOI: 10.1007/s00535-022-01940-1. [10] CHHATWAL J, SAMUR S, KUES B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list[J]. Hepatology, 2017, 65( 3): 777- 788. DOI: 10.1002/hep.28926. [11] TERRAULT NA, BERENGUER M, STRASSER SI, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant recipients[J]. Transplantation, 2017, 101( 5): 956- 967. DOI: 10.1097/TP.0000000000001704. [12] PRENNER SB, VANWAGNER LB, FLAMM SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals[J]. J Hepatol, 2017, 66( 6): 1173- 1181. DOI: 10.1016/j.jhep.2017.01.020. [13] CARRION AF, KHADERI SA, SUSSMAN NL. Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation[J]. Liver Transpl, 2016, 22( 3): 279- 280. DOI: 10.1002/lt.24383. [14] PICCIOTTO FP, TRITTO G, LANZA AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation[J]. J Hepatol, 2007, 46( 3): 459- 465. DOI: 10.1016/j.jhep.2006.10.017. [15] SAXENA V, KHUNGAR V, VERNA EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study[J]. Hepatology, 2017, 66( 4): 1090- 1101. DOI: 10.1002/hep.29258. [16] KWOK RM, AHN J, SCHIANO TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients[J]. Liver Transpl, 2016, 22( 11): 1536- 1543. DOI: 10.1002/lt.24614. [17] POORDAD F, SCHIFF ER, VIERLING JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence[J]. Hepatology, 2016, 63( 5): 1493- 1505. DOI: 10.1002/hep.28446. [18] MARINAKI S, BOLETIS JN, SAKELLARIOU S, et al. Hepatitis C in hemodialysis patients[J]. World J Hepatol, 2015, 7( 3): 548- 558. DOI: 10.4254/wjh.v7.i3.548. [19] MATHURIN P, MOUQUET C, POYNARD T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome[J]. Hepatology, 1999, 29( 1): 257- 263. DOI: 10.1002/hep.510290123. [20] INGSATHIT A, KAMANAMOOL N, THAKKINSTIAN A, et al. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: A systematic review and meta-analysis[J]. Transplantation, 2013, 95( 7): 943- 948. DOI: 10.1097/TP.0b013e3182848de2. [21] COLOMBO M, AGHEMO A, LIU H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial[J]. Ann Intern Med, 2017, 166( 2): 109- 117. DOI: 10.7326/M16-1205. [22] FERNÁNDEZ I, MUÑOZ-GÓMEZ R, PASCASIO JM, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C[J]. J Hepatol, 2017, 66( 4): 718- 723. DOI: 10.1016/j.jhep.2016.12.020. [23] HUSSEIN NR, SALEEM ZSM. Successful treatment of hepatitis C virus genotype 4 in renal transplant recipients with direct-acting antiviral agents[J]. Am J Transplant, 2016, 16( 7): 2237- 2238. DOI: 10.1111/ajt.13767. [24] KAMAR N, MARION O, ROSTAING L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation[J]. Am J Transplant, 2016, 16( 5): 1474- 1479. DOI: 10.1111/ajt.13518. [25] D’AMBROSIO R, AGHEMO A, ROSSETTI V, et al. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: Case series and review of the literature[J]. Liver Int, 2016, 36( 11): 1585- 1589. DOI: 10.1111/liv.13203. [26] LIU CH, CHEN YS, WANG SS, et al. Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection[J]. Clin Infect Dis, 2018, 66( 2): 289- 292. DOI: 10.1093/cid/cix787. [27] DOUCETTE K, SUMNER S, WEINKAUF J. Treatment of hepatitis C in a lung transplant recipient with sofosbuvir and daclatasvir[J]. J Heart Lung Transplant, 2016, 35( 6): 840- 841. DOI: 10.1016/j.healun.2016.01.1219. [28] BARI K, LUCKETT K, KAISER T, et al. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients[J]. Hepatology, 2018, 67( 5): 1673- 1682. DOI: 10.1002/hep.29704. [29] LUCKETT K, KAISER TE, BARI K, et al. Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients[J]. J Am Coll Surg, 2019, 228( 4): 560- 567. DOI: 10.1016/j.jamcollsurg.2018.12.004. [30] KWONG AJ, WALL A, MELCHER M, et al. Liver transplantation for hepatitis C virus(HCV) non-viremic recipients with HCV viremic donors[J]. Am J Transplant, 2019, 19( 5): 1380- 1387. DOI: 10.1111/ajt.15162. [31] BETHEA E, ARVIND A, GUSTAFSON J, et al. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning[J]. Am J Transplant, 2020, 20( 6): 1619- 1628. DOI: 10.1111/ajt.15768. [32] KAPILA N, MENON KVN, AL-KHALLOUFI K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience[J]. Hepatology, 2020, 72( 1): 32- 41. DOI: 10.1002/hep.31011. [33] AQEL B, WIJARNPREECHA K, PUNGPAPONG S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients[J]. J Hepatol, 2021, 74( 4): 873- 880. DOI: 10.1016/j.jhep.2020.11.005. [34] GOLDBERG DS, ABT PL, BLUMBERG EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients[J]. N Engl J Med, 2017, 376( 24): 2394- 2395. DOI: 10.1056/nejmc1705221. [35] REESE PP, ABT PL, BLUMBERG EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: A single-group trial[J]. Ann Intern Med, 2018, 169( 5): 273- 281. DOI: 10.7326/M18-0749. [36] GUPTA G, YAKUBU I, BHATI CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients[J]. Am J Transplant, 2020, 20( 3): 739- 751. DOI: 10.1111/ajt.15664. [37] DURAND CM, BARNABA B, YU S, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: An open-label nonrandomized study[J]. Ann Intern Med, 2021, 174( 1): 137- 138. DOI: 10.7326/M20-1468. [38] SISE ME, GOLDBERG DS, KORT JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys(MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection[J]. J Am Soc Nephrol, 2020, 31( 11): 2678- 2687. DOI: 10.1681/ASN.2020050686. [39] LA HOZ RM, SANDıKÇı B, ARIYAMUTHU VK, et al. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals[J]. Am J Transplant, 2019, 19( 11): 3058- 3070. DOI: 10.1111/ajt.15496. [40] SCHLENDORF KH, ZALAWADIYA S, SHAH AS, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies[J]. J Heart Lung Transplant, 2018, 37( 6): 763- 769. DOI: 10.1016/j.healun.2018.01.1293. [41] SCHLENDORF KH, ZALAWADIYA S, SHAH AS, et al. Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C[J]. JAMA Cardiol, 2020, 5( 2): 167. DOI: 10.1001/jamacardio.2019.4748. [42] KILIC A, HICKEY G, MATHIER M, et al. Outcomes of adult heart transplantation using hepatitis C-positive donors[J]. J Am Heart Assoc, 2020, 9( 2): e014495. DOI: 10.1161/JAHA.119.014495. [43] MOAYEDI Y, FAN CPS, GULAMHUSEIN AF, et al. Current use of hearts from hepatitis C viremic donors[J]. Circ Heart Fail, 2018, 11( 12): e005276. DOI: 10.1161/circheartfailure.118.005276. [44] ALTSHULER PJ, HELMERS MR, SCHIAZZA AR, et al. HCV-positive allograft use in heart transplantation is associated with increased access to overdose donors and reduced waitlist mortality without compromising outcomes[J]. J Card Fail, 2022, 28( 1): 32- 41. DOI: 10.1016/j.cardfail.2021.07.007. [45] WOOLLEY AE, SINGH SK, GOLDBERG HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients[J]. N Engl J Med, 2019, 380( 17): 1606- 1617. DOI: 10.1056/NEJMoa1812406. [46] BETHEA ED, GAJ K, GUSTAFSON JL, et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: An open-label study[J]. Lancet Gastroenterol Hepatol, 2019, 4( 10): 771- 780. DOI: 10.1016/S2468-1253(19)30240-7. [47] FELD JJ, CYPEL M, KUMAR D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 7): 649- 657. DOI: 10.1016/S2468-1253(20)30081-9. [48] ABDELBASIT A, HIRJI A, HALLORAN K, et al. Lung transplantation from hepatitis C viremic donors to uninfected recipients[J]. Am J Respir Crit Care Med, 2018, 197( 11): 1492- 1496. DOI: 10.1164/rccm.201712-2614le. [49] SMITH DE, CHEN S, FARGNOLI A, et al. Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors[J]. Semin Thorac Cardiovasc Surg, 2021, 33( 2): 407- 415. DOI: 10.1053/j.semtcvs.2020.06.045. [50] CYPEL M, FELD JJ, GALASSO M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: An open-label, single-centre, pilot trial[J]. Lancet Respir Med, 2020, 8( 2): 192- 201. DOI: 10.1016/S2213-2600(19)30268-1. [51] ECKMAN MH, WOODLE ES, THAKAR CV, et al. Transplanting hepatitis C virus-infected versus uninfected kidneys into hepatitis C virus-infected recipients[J]. Ann Intern Med, 2018, 169( 4): 214. DOI: 10.7326/m17-3088. [52] CORTESI PA, BELLI LS, FACCHETTI R, et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities[J]. J Viral Hepat, 2018, 25( 7): 791- 801. DOI: 10.1111/jvh.12877. -
本文二维码
计量
- 文章访问数: 295
- HTML全文浏览量: 147
- PDF下载量: 53
- 被引次数: 0
下载:
